These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 11486404)

  • 21. Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma.
    Magagnoli M; Sarina B; Balzarotti M; Castagna L; Timofeeva I; Nozza A; Bertuzzi A; Siracusano L; Sinnone M; Santoro A
    Bone Marrow Transplant; 2001 Nov; 28(10):923-7. PubMed ID: 11753545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mobilisation of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (Filgrastim) in patients with malignant lymphomas or solid tumours.
    Baars JW; Holtkamp MJ; Nooyen WJ; Walll EV; Te Velde A; Dalesio O; Slaper-Cortenbach IC; Schoot EV; Richel DJ; Gerritsen WR; Schornagel JH; Rodenhuis S
    Anticancer Res; 1996; 16(5B):3089-95. PubMed ID: 8920773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL.
    Flohr T; Hess G; Kolbe K; Gamm H; Nolte H; Stanislawski T; Huber C; Derigs HG
    Bone Marrow Transplant; 2002 May; 29(9):769-75. PubMed ID: 12040475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
    Damon L; Rugo H; Tolaney S; Navarro W; Martin T; Ries C; Case D; Ault K; Linker C
    Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Use of Mabtera (rituximab) in treating patients with refractory courses of B-cell lymphoma, along with high-dose chemotherapy and autologous transplantation of hematopoietic stem cells].
    Ptushkin VV; Chimishkian KL; Zhukov NV; Osmanov DSh; Andreeva LIu; Tupitsyn NN; Larionova VB; Mkheidze DM; Poddubnaia NV
    Ter Arkh; 2003; 75(1):65-8. PubMed ID: 12652962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation.
    Lee CK; de Magalhaes-Silverman M; Hayashi M; Schlueter A; Strauss RG; Hohl RJ; Gingrich RD
    Bone Marrow Transplant; 2002 Apr; 29(8):647-52. PubMed ID: 12180108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
    Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
    Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pilot study of tandem high-dose chemotherapy and autologous stem cell transplantation with a novel combination of regimens in patients with poor risk lymphoma.
    Papadopoulos KP; Noguera-Irizarry W; Wiebe L; Hesdorffer CS; Garvin J; Nichols GL; Vahdat LH; Lo KM; Skerrett D; Bernstein D; Sharpe E; Savage DG
    Bone Marrow Transplant; 2005 Sep; 36(6):491-7. PubMed ID: 16044139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.
    Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; Gonin R; McCauley M; Mazanet R; Schnipper L; Frei E
    Bone Marrow Transplant; 1995 Mar; 15(3):373-9. PubMed ID: 7599561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
    Salar A; Martino R; Perea G; Ribera JM; López-Guillermo A; Guardia R; Escoda L; Altés A; Sierra J; Montserrat E
    Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].
    Hirose A; Yamane T; Nakajima Y; Manabe M; Kanashima H; Hagihara K; Sakamoto E; Nakamae M; Terada Y; Kosaka S; Aoyama Y; Sakamoto C; Kumura T; Koh KR; Hirai M; Ohta K; Nakao Y; Mugitani A; Teshima H; Hino M
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2059-64. PubMed ID: 16352929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT).
    Joyce RM; Regan M; Ottaway J; Umiel T; Tetreault JC; Levine J; McDermott D; Hurley D; Giallombardo N; Smith T; Lamontagne D; Uhl L; Avigan D
    Ann Oncol; 2003; 14 Suppl 1():i21-7. PubMed ID: 12736227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma.
    Hess G; Flohr T; Kolbe K; Bonn S; Schuler M; Derigs HG; Huber C
    Ann Hematol; 2006 Nov; 85(11):769-79. PubMed ID: 16896912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin's lymphoma.
    Tsirigotis P; Dray L; Resnick IB; Ackerstein A; Gesundheit B; Elad S; Or R; Shapira MY
    Ann Hematol; 2010 Mar; 89(3):263-72. PubMed ID: 19693502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
    Kanaji N; Ishibashi K; Uno H; Hino N
    Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions.
    Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; McCauley M; Mazanet R; Schnipper L; Frei E; Antman KH
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):83-5. PubMed ID: 7992072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Chemotherapy of resistant and recurrent lymphoma based on a combination of ifosfamide and etoposide. Antitumor effects, toxicity and stimulation of peripheral stem cells].
    Mayer J; Korístek Z; Vásová I; Müllerová I; Král Z; Navrátil M; Klabusay M; Vorlícek J; Vodvárka P; Hejlová N; Penka M; Krahulcová E; Tomíska M; Adam Z; Hájek R
    Cas Lek Cesk; 1998 Oct; 137(19):590-7. PubMed ID: 9818471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience.
    Jerkeman M; Leppä S; Kvaløy S; Holte H
    Eur J Haematol; 2004 Sep; 73(3):179-82. PubMed ID: 15287915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B.
    Nademanee A; Forman SJ
    Semin Hematol; 2006 Oct; 43(4):240-50. PubMed ID: 17027658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.